about
Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation.Cord-Blood Transplantation in Patients with Minimal Residual DiseaseImpact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation.Langerhans cell homeostasis and turnover after nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation.Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioningGraft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Mesenchymal stromal cells fail to prevent acute graft-versus-host disease and graft rejection after dog leukocyte antigen-haploidentical bone marrow transplantation.Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives.Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria.Telomere shortening in hematopoietic stem cell transplantation: a potential mechanism for late graft failure?A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells.Pharmacological immunosuppression reduces but does not eliminate the need for total-body irradiation in nonmyeloablative conditioning regimens for hematopoietic cell transplantationNon-myeloablative hematopoietic cell transplantation as immunotherapy for hematologic malignancies.Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantationLong-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignanciesCanine bone marrow-derived mesenchymal stromal cells suppress alloreactive lymphocyte proliferation in vitro but fail to enhance engraftment in canine bone marrow transplantation.Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial.CD34 cell dose and chronic graft-versus-host disease after human leukocyte antigen-matched sibling hematopoietic stem cell transplantation.Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation.Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model.Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrowNonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation.Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors.Identification and characterization of canine dendritic cells generated in vivo.Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantationAllogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects.Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors.Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target.CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemiaInitial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes.Establishment of long-term tolerance to SRBC in dogs by recombinant canine CTLA4-Ig.Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease.Hematopoietic Cell Transplantation after Solid Organ Transplantation.Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.
P50
Q33677489-E8EE3404-3F2F-462B-B662-CE02CF0D9305Q33911314-C8BAF2DB-5DF0-4763-9BE2-48026273060AQ34106362-5BAA3221-8FE2-4953-B50F-D3CCC3A57A2FQ34111627-6CF54B8A-E539-4356-824A-8BCBCDF83A60Q34186689-7E9669AE-4CF9-4068-AF9B-89F2A31AFD7CQ34402494-4541C989-8F7F-4B81-9A47-1E2AD335D66DQ34404171-46BCFC2D-3C8D-490B-9C7A-CB99180520E0Q34520475-FA1F40A6-A157-46B4-934F-301B61FCF683Q34630152-5E91580D-FC08-4BC7-817D-273584A87785Q34707280-72CA74C9-CDFB-4E8D-8893-99123DF856B0Q35015447-59355FA1-CF22-477A-B759-7F35E0974D62Q35042830-3AE90C16-EB2A-4FFF-9B55-89AE79CE34D8Q35109158-40E327C5-B565-418E-9BE6-EB4D48658F60Q35202894-5D7D5A28-AFB6-4BE0-A917-8314299708D7Q35465005-4E843278-9ECA-4058-9052-6A2E431A5F9FQ35554703-89CE6BDC-DAEE-4FF8-92DA-E68FA52659CDQ35599947-07F4F3DB-C40A-4EF6-BE83-ECA8519D5EA1Q35669901-A8655F41-0C79-403B-8B5F-F8DDF2949776Q35733259-4C875E0F-69C4-44CF-B58C-7DDA5499DEA1Q35748508-0F671CD9-89DE-4439-94C5-D94CA7A0D0BDQ35847785-3EA04950-3F80-43AF-AC22-5560883BC224Q35849351-1FFCF76E-DEEA-48AB-9169-830BB5EC8B41Q35946619-C041D08F-DACE-48F0-90ED-739D795C725DQ36007719-E6326A0F-7970-4076-B93F-78D2D2B3387BQ36234484-FC7CE747-57A6-4426-B261-728E9C7B6FCCQ36320260-82C3474E-D1F8-4A87-BAB5-72B6F6CB6534Q36343056-3B307D63-85DE-4260-89CC-ED477B663088Q36700499-26300133-3CC3-4428-AE26-90AB9FDE7727Q36763834-9EFEF660-936F-4DC0-97C4-D190A8C3D0E9Q36774150-580990FB-8876-4373-8A4A-97721D84A732Q36914475-AED52757-6D74-4757-95C8-FE52149BC9B4Q36926722-437950F6-4B47-41E1-A498-C2EAE3A1C078Q36966278-70B77908-C9FA-4D79-8FD7-41279FCFA7A2Q37098861-1D4B1C77-3E4F-498B-879E-6DCD0D8F2823Q37143633-FDB1CDAD-22AA-4C4D-924C-D8EEAF9C4EC0Q37366120-A1FF4DCA-4439-41D3-B28B-6CDB4AE5044FQ37552088-9F23A3E6-C17F-4FCE-8B7D-635E4DBC7DF5Q38566126-B9D75E9C-7D46-4B23-92F0-250D7A323611Q39002077-BEBFB55B-E338-4CA7-ACB6-24EF186C91EEQ39042251-FDF04EDC-B79E-411D-BF12-F70EA68CFFB8
P50
name
Marco Mielcarek
@en
Marco Mielcarek
@nl
type
label
Marco Mielcarek
@en
Marco Mielcarek
@nl
prefLabel
Marco Mielcarek
@en
Marco Mielcarek
@nl